Previous Next Accountability Remdesivir’s hefty price tag ignores NIH investment in its creation Abstract: Gilead said it spent $1 billion to develop remdesivir. The NIH invested as much as $6.5 billion in it between 2000 and 2019. Publication: STAT Date Published: October 22, 2020 Author(s): Ekaterina Cleary View This Resource